Appili Therapeutics Inc Cash Flow Conversion Efficiency
Appili Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Appili Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Appili Therapeutics Inc (APLI) share price today for real-time trading data and today's change.
Appili Therapeutics Inc Cash Flow Conversion Ratio Explained
Appili Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Appili Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MOVEBYBIKE EUROPE AB
F:6ZR
|
-7.892x |
|
Jersey Oil and Gas PLC
LSE:JOG
|
-0.012x |
|
Watkin Jones PLC
LSE:WJG
|
-0.050x |
|
PURANIUM ENERGY LTD.
F:2DK
|
0.113x |
|
Setubandhan Infrastructure Limited
NSE:SETUINFRA
|
0.000x |
|
Naked Wines plc
LSE:WINE
|
0.096x |
|
Purple Biotech Ltd
TA:KTOV
|
-0.041x |
|
SECITS Holding AB (publ)
ST:SECI
|
0.666x |
Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. Review Appili Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$-13.40 Million ≈ $-9.69 Million |
CA$868.82K ≈ $628.49K |
-0.065x | -128.75% |
| 2024-03-31 | CA$-10.92 Million ≈ $-7.90 Million |
CA$-2.46 Million ≈ $-1.78 Million |
0.226x | -83.48% |
| 2023-03-31 | CA$-7.40 Million ≈ $-5.35 Million |
CA$-10.10 Million ≈ $-7.30 Million |
1.365x | -76.60% |
| 2022-03-31 | CA$-3.27 Million ≈ $-2.37 Million |
CA$-19.08 Million ≈ $-13.80 Million |
5.834x | +749.77% |
| 2021-03-31 | CA$12.75 Million ≈ $9.23 Million |
CA$-11.45 Million ≈ $-8.28 Million |
-0.898x | -86.42% |
| 2020-03-31 | CA$8.85 Million ≈ $6.40 Million |
CA$-4.26 Million ≈ $-3.08 Million |
-0.482x | +38.42% |
| 2019-03-31 | CA$4.42 Million ≈ $3.20 Million |
CA$-3.46 Million ≈ $-2.50 Million |
-0.782x | -15.22% |
| 2018-03-31 | CA$4.87 Million ≈ $3.52 Million |
CA$-3.30 Million ≈ $-2.39 Million |
-0.679x | +56.34% |
| 2017-03-31 | CA$1.37 Million ≈ $994.41K |
CA$-2.14 Million ≈ $-1.55 Million |
-1.555x | -- |
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more